Premium
Validation of 1‐year predictive score of long‐term response to interferon‐β in everyday clinical practice multiple sclerosis patients
Author(s) -
Romeo M.,
Martinelli V.,
Rodegher M.,
Perego E.,
Maida S.,
Sormani M. P.,
Comi G.
Publication year - 2015
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.12695
Subject(s) - medicine , multiple sclerosis , expanded disability status scale , cohort , hazard ratio , multivariate analysis , proportional hazards model , clinical practice , cohort study , physical therapy , confidence interval , immunology
Background and purpose The Rio score ( RS ) and the modified Rio score ( MRS ) are two scoring systems that can identify the early predictive factors of disability progression in relapsing−remitting multiple sclerosis ( RRMS ) patients treated with interferon‐β ( IFN ‐β). The objective of the study was to validate the usefulness of the RS and MRS in a large cohort of multiple sclerosis patients treated with IFN ‐β in daily clinical practice. Methods The analysis included a cohort of RRMS patients treated with different formulations of IFN ‐β for at least 1 year. The RS and MRS were used to classify the patients after 1 year of treatment. Multivariate analysis was performed to identify predictive variables of suboptimal response at 5 years, defined as Expanded Disability Status Scale confirmed progression or switching to a second‐line therapy. Results Sixty‐nine of 416 included patients were considered as suboptimal responders at 5‐year evaluation. The possible score range was 0–3. A higher risk of suboptimal response was found for RS and MRS in the presence of ≥2 scores (hazard ratio 3.0, P = 0.002, and hazard ratio 5.0, P < 0.0001, respectively). Conclusions Our study confirmed, in a daily clinical setting, that MRS had a better specificity and accuracy than RS in identifying the patients who will have a poor response to long‐term IFN ‐β treatment.